Seroatlas · Human Serome Atlas

STEAP1

STEAP1 protein

Also known as: PRSS24, STEA1_HUMAN, STEAP

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UHE8
Gene: STEAP1
Ensembl: ENSG00000164647
Chromosome: 7
Canonical length: 339 aa
Protein class: Cancer-related genes, Predicted membrane proteins, Transporters
Quaternary structure: Homotrimer

OverviewNCBI Gene

This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

339 residues, UniProt reviewed canonical sequence.

>Q9UHE8|STEAP1
     1  MESRKDITNQ EELWKMKPRR NLEEDDYLHK DTGETSMLKR PVLLHLHQTA HADEFDCPSE
    61  LQHTQELFPQ WHLPIKIAAI IASLTFLYTL LREVIHPLAT SHQQYFYKIP ILVINKVLPM
   121  VSITLLALVY LPGVIAAIVQ LHNGTKYKKF PHWLDKWMLT RKQFGLLSFF FAVLHAIYSL
   181  SYPMRRSYRY KLLNWAYQQV QQNKEDAWIE HDVWRMEIYV SLGIVGLAIL ALLAVTSIPS
   241  VSDSLTWREF HYIQSKLGIV SLLLGTIHAL IFAWNKWIDI KQFVWYTPPT FMIAVFLPIV
   301  VLIFKSILFL PCLRKKILKI RHGWEDVTKI NKTEICSQL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against STEAP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 6
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 79 nTPM

Expression across tissuesHPA

Tissue

prostate: 79 nTPM
urinary bladder: 32 nTPM
appendix: 31 nTPM
adipose tissue: 31 nTPM
liver: 28 nTPM
smooth muscle: 25 nTPM

Single-cell type

prostatic glandular cells: 235 nCPM
gastric progenitor cells: 99 nCPM
respiratory secretory cells: 88 nCPM
prostatic club cells: 79 nCPM
epicardial cells: 55 nCPM
mesothelial cells: 51 nCPM

Immune cell

myeloid DC: 0.2 nTPM
memory B-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

cerebral cortex: 2.6 nTPM
choroid plexus: 1.8 nTPM
basal ganglia: 1.7 nTPM
medulla oblongata: 1.5 nTPM
white matter: 1.2 nTPM
hypothalamus: 1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about STEAP1.

Disease | ImmuneIEDB

Conditions an epitope on STEAP1 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.2
gnomAD pLI: 0
gnomAD missense Z: 0.12
DepMap mean gene effect: 0.12
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads STEAP1 as an antibody target. Whether an autoantibody or antibody against STEAP1 could matter depends on whether native STEAP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

STEAP1 is annotated at the cell surface, where native STEAP1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label STEAP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...